Let’s see if BP gives any value. Saying that it is best product does not mean anything
B-ABSSI was considered new class of ABX, would get early approval and BPs will jump on it and give great price (based on cubist purchase by Merck) - but nothing has happened after 2+ years.
So it is like beauty is in eyes of beholder - so value of any product is in eyes of market or BP